/
Despite recent scientific advances in genetics, most neurological diseases, particularly those with devastating consequences to patients, are left untreated. Conventional gene therapy is an attractive potential treatment approach for only a limited number of monogenic diseases due to the challenges caused by the complex biology of neurological diseases and by inherent variable transgene uptake …
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
ROIC dropped from -24.92% to -27.32%, capital efficiency is deteriorating. Negative free cash flow of -$78M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$99M
▼ -20.2% YoY
Op. Margin
—
ROIC
-32.36%
▼ -2.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$83M
▼ -9.7% YoY
Op. Cash Flow (TTM)
-$83M
▼ -9.3% YoY
Net Debt
-$234M
Net Cash Position
Cash & Equiv.
$243M
Continue Research